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Introduction
The γ-secretase complex is a multi-subunit, intramembrane pro-
tease (reviewed1). It cleaves type-I single-pass transmembrane 
proteins within their transmembrane domain. This can lead 
to the release of an intracellular and an extracellular domain 
that may perform other functions. Examples include the cleav-
age of amyloid precursor protein (APP) to produce amyloid beta 
and the cleavage of activated NOTCH receptors to release their 
intracellular domain for translocation to the nucleus2.
Gamma-secretase is composed of several proteins, includ-
ing a presenilin protease (PSEN1 or PSEN2), the preseni-
lin enhancer gamma-secretase subunit (PEN2), an anterior 
pharynx-defective 1 protein (APH1A or APH1B), and nicastrin 
(NCSTN)3. Nicastrin acquires extensive N-linked glycosylation 
during its maturation4,5, though the glycosylation may not be 
required for typical cleavage activity6. The three-dimensional 
structure of human gamma-secretase shows that the heavily gly-
cosylated ectodomain of nicastrin forms a horseshoe-like clamp 
on the extracellular portion of the complex7,8. It is thought that 
NCSTN may help control substrate selectivity9. Understanding 
the role of nicastrin in gamma-secretase has been challenging. 
Gamma-secretase can cleave many substrates without nicas-
trin, though nicastrin does help to exclude some substrates via 
steric hindrance10–12. There are multiple commercial antibod-
ies for NCSTN available, but they do not agree on the expected 
product size. We validated one commercial polyclonal anti-




We used a commercially available rabbit anti-human IgG 
polyclonal antibody that targets human nicastrin (#N1660; 
Sigma-Aldrich, St. Louis, MO, USA; RRID:AB_477259) which 
is has performed well in some previous publications13,14. The 
antibody was raised against Uniprot nicastrin peptide Q92542 
(709 amino acid total size). The polyclonal was generated by 
challenging rabbits with a synthetic peptide corresponding 
to the C-terminal cytoplasmic domain of nicastrin (peptides 
693-709) fused with keyhole limpet hemocyanin as an adjuvant.
The technical documentation claims this subsequence is identi-
cal to the matching region of nicastrin in mouse. However, align-
ing Q92542 to the primary mouse nicastrin peptide sequence 
(NP_067620.3) with Clustal Omega15,16 actually shows 1 mis-
match (94.1% identity; Figure 1). It’s unclear if this discrep-
ancy is due to changes to either the human or mouse peptide 
sequence for the most common isoform over time as the 
references have been updated.
We used a mouse anti-human beta actin monoclonal anti-
body (#AB6276; Abcam, Cambridge, MA, USA; RRID: 
AB_2223210) as a loading control. The details of all primary 
and secondary antibodies are summarized in Table 1.
Figure 1. Human / mouse nicastrin alignment. Shown is a partial alignment between human and mouse nicastrin. The highlighted area 
represents the peptides use for generation of the polyclonal antibody. Asterisks represent a matching amino acid between the two sequences, 
and spaces are mismatches.
Table 1. Details of the primary and secondary antibodies.
Antibody (Ab) Manufacturer Catalog 
Number
RRID Lot number Ab 
species
Ab type
Anti-Nicastrin Sigma N1660 AB_477259 076M4843V rabbit polyclonal 
Anti-beta Actin (AC-15) abcam ab6276 AB_2223210 GR181659-16 mouse monoclonal 
Goat Anti-Rabbit IgG 
(H&L)- HRPO
Leinco Technologies R115 AB_2810875 0117L320 goat polyclonal 




115-035-003 AB_10015289 129457 goat polyclonal 
      Amendments from Version 1
The major change in this revision is the addition of a blot showing 
the antibody works with murine-derived protein as well. Otherwise 
we have revised the manuscript to alter some language and 
include important references suggested by the reviewers. There 
is also new underlying data for this figure that has been uploaded 
to FigShare. 
Any further responses from the reviewers can be found at the 
end of the article
REVISED
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Cell lines and culture
We purchased the Human Embryonic Kidney cell line 
(HEK293) from the ATCC (CRL-1573). We cultured all cells 
at 37°C and 5% CO2. For culture media, we used Dulbecco’s 
Modified Eagle’s Media (DMEM; Gibco, Thermo-Fisher 
Scientific, #11965-084) supplemented with 5% Fetal Bovine 
Serum (FBS; Gibco, Thermo-Fisher Scientific, #26140-079), 1% 
HEPES (Corning, #25-060-CI), 100 U/mL penicillin / streptomy-
cin (Gibco, Thermo-Fisher Scientific, #15140-122), and 2 mM 
glutamine (Corning, #25-005-CI).
HEK293 NCSTN knockout line
We used a HEK293 NCSTN knockout line we had previously 
generated using CRISPR/Cas9 genome-editing17. Briefly, we 
synthesized our single-guide RNA as an IDT gBlock and cloned 
it into the pCR-Blunt TOPO vector. We co-transfected the 
single-guide RNA vector along with humanized Cas9 (RRID: 
Addgene_43861) into HEK293 cells, plated to single colonies, 
and screened for deleted clones by sequencing (Sequence Read 
Archive project PRJNA268374) and RT-qPCR (Data available 
from figshare, see source data18). Full methodology for RT-qPCR 
is provided in the supplementary material of Cao et al.17
Cell line protein extraction
Reagent details can be found in Table 2 and Table 3. We harvested 
cells at ≥90% confluence and pelleted them by centrifugation 
at 4°C and 400 ×g for 5 minutes. We washed the cell pellet 
three times in 10 mL of cold phosphate buffered saline (PBS). 
We then added 300 µL of cold lysis buffer (50 mM Tris-HCl 
pH 8.0, 2 mM EDTA, 150 mM NaCl, 1.0% NP-40, and 1.5% 
protease inhibitor cocktail) and lysed the cells with con-
stant agitation for 30 minutes at 4°C. We removed insoluble 
debris by centrifugation for 15 minutes at 4°C and 10,400 ×g. 
We determined the concentration of the cleared lysates using 
a Pierce BCA assay kit (#23227). We stored the lysates in 
aliquots at -80°C until further use.
Mouse liver protein extraction
We received a snap-frozen mouse liver (2 month-old C57BL/6 
mouse) from the Alfred Kim lab, which had been obtained 
according to their approved IACUC protocol. We minced the 
liver into pieces and homogenized in ice-cold lysis buffer 
(5 mM Tris-HCl pH 8.0, 250 mM sucrose, 5 mM EDTA, 1.5% 
protease inhibitor cocktail) using a Wheaton tissue grinder. We 
then passed the solution through a QIAshredder spin-column 
(Qiagen #79656) to facilitate more complete lysis. We spun 
cellular debris out of solution by a 5 minute spin at 5,000 xg. 
We then precipitated membrane-enriched fragments by spinning 
for 5 minutes at 11,000 xg (4°C), then spinning the superna-
tant for an additional 1 hour at 4°C and 11,000 xg. We then 
extracted proteins from the membrane pellet by resuspending 
in buffer containing 2% (v/v) Triton X-100 and incubating 
on ice for 30 minutes. Any remaining unlysed material was 
pelleted with a 1 hour, 4°C, 11,000 xg spin. We determined the 
protein concentration of the lysate using the Pierce BCA assay 
kit. We stored lysates in aliquots at -80°C until blotting. 
Table 2. Details of Cell lysis reagents.
Reagent Manufacturer Catalog Number
1M Tris–HCl pH 8 Corning 46-031-CM
0.5M EDTA pH8 Corning 46-034-Cl




Protease Inhibitor Cocktail Sigma P8340
Sucrose Sigma S1888
Triton X-100 Sigma T8787
Table 3. Details of SDS-PAGE / Immunoblotting reagents.
Protocol Steps Reagents Manufacturer Catalog Number
Protein concentration 
measurement 
Pierce BCA Protein assay kit Thermo Scientific 23227
Cell lysate preparation 2x Laemmli sample buffer β-mercaptoethanol Biorad Sigma 161-0737 M3148






Immunoblotting Immobilon-P PVDF Membrane (0.45 µm) 
2-Propanol 










Chemiluminescence reaction SuperSignal West Pico Chemiluminescent Substrate Thermo Scientific 34080
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Enzymatic deglycosylation
We used peptide-N-glycosidase F (PNGase F; #P0704S; New 
England Biolabs, Ipswich, MA, USA) to remove N-linked 
sugars. We denatured about 50 µg of protein in glycoprotein 
denaturing buffer (included with NEB kit; 0.5% SDS, 40 mM 
DTT) at 100°C for 10 minutes, and then incubated the lysate with 
PNGase F for 3 hours at 37°C, according to the manufacturer’s 
instructions. We treated a control in parallel under the same 
conditions, but omitted the PNGase F enzyme.
Immunoblotting
We denatured the protein lysate by boiling for 5 minutes in 
Laemmli sample buffer (5% β-mercaptoethanol). We resolved 
the proteins on precast 7.5% polyacrylamide gels (Mini-protean 
TGX; Bio-Rad, Hercules, CA, USA) after loading approxi-
mately 20 µg of lysate. We used the Precision Plus Dual-Color 
Standard as a molecular weight marker (Bio-Rad, Hercules, 
CA). We prepared PVDF membranes (0.45 µm) by incubating 
2 minutes in 100% isopropanol, washing in Milli-Q water for 
2 minutes, and equilibrating in transfer buffer for 10 minutes. 
We transferred separated proteins to the PVDF membrane in 
transfer buffer without methanol at 200 mA for 2 hours. We 
blocked the membrane by incubating in blocking buffer (TBST 
with 5% skim milk powder) for 1 hour at room temperature 
with gentle rocking. We probed the membrane using primary 
antibodies to nicastrin (1/1000) and beta actin (1/5000) 
diluted in blocking buffer overnight at 4°C with gentle rock-
ing. We removed excess unbound antibody by rinsing the 
membranes 5 times for 10 minutes each in TBST buffer. The 
anti-mouse and anti-rabbit secondary antibodies were both con-
jugated to horseradish peroxidase (HRP). We incubated the 
membranes with secondary antibody (1/7000) in blocking 
buffer for 1.5 hours at room temperature, followed by washing 
5 times for 10 minutes each in TBST. We used the Supersignal 
West Pico Chemiluminescent Substrate reagent (ThermoFisher, 
Waltham, MA) to detect secondary antibodies.
Results
The nicastrin polyclonal binds to endogenous nicastrin in 
HEK293 extracts
We collected protein lysates from wildtype HEK293 cells 
and HEK293 NCSTN knockouts. The manufacturer provided 
example blots were derived from HEK293 cells, but used an 
overexpression construct. In wildtype HEK293 cell lysates, 
a single, strong band at ~110 kDa can be seen on the blot, 
and this band is missing in the nicastrin knockout line lysates 
(Figure 2A, underlying data19,20). The loading controls for 
the wildtype replicates and knockout replicates all show the 
expected band for actin (Figure 2B, underlying data19,20), sup-
porting that the loss of the nicastrin band is specific to the 
knockout and not a loading error. It is worth noting that despite 
a low background, the nicastrin blots showed an approxi-
mately 25 kDa band in both wildtype and knockout lysates. We 
searched the protein sequence used to develop the antibody 
(KADVLFIAPREPGAVSY) with protein blast using the Homo 
sapiens non-redundant peptide database automatically adjusted 
for short queries, but only matches to nicastrin had a reason-
able e-value (2×10-9 to 7×10-11). It is therefore unclear if this 
band is from a non-specific contaminant in the antibody, a 
similar peptide that is poorly annotated in the non-redundant 
protein database, or a nicastrin degradation product.
The larger than expected band size for nicastrin is due to 
glycosylation
The nicastrin antibody documentation lists the expected frag-
ment size as approximately 110 kDa, and this band size was con-
firmed on our blots. However, calculating the fragment size of 
human nicastrin protein sequence Q92542 using Expasy tools21 
gives an estimated 78.4 kDa size for the nascent fragment and 
a reduced 75.2 kDa size after cleavage of the signal peptide. 
We hypothesized this discrepancy might be due to glycosylation.
We tested this hypothesis by first treating the lysates PNGase F, 
which will release asparagine-linked oligosaccharides. This 
reduced the molecular weight of the nicastrin band to less than 
75 kDa (Figure 3A, underlying data22,23) without affecting the 
actin band (Figure 3B underlying data22,23). This phenomenon 
of a smaller than expected nicastrin band has been observed 
previously6,24. It is possible that a longer signal sequence 
than expected is cleaved from the nascent peptide. Given that 
detailed information is available for the signal cleavage of 
nicastrin9, a more likely explanation might be that the charge 
profile of the polypeptide affects its migration.
The antibody binds to endogenous mouse nicastrin
As noted above, there were mismatches between the sequence 
used to generate the antibody and the mouse sequence for 
nicastrin. It was possible that this mismatch was enough to 
reduce the effectiveness of this antibody in mouse extracts. We 
extracted protein from frozen mouse liver to test this possibility. 
We were able to confirm the presence of a band of the expected 
size in the mouse extracts (Figure 4, underlying data25). The 
same small, non-specific band was present in these blots as well.
Figure 2. Immunoblot of endogenous nicastrin. A. The NCSTN 
antibody binds to endogenous levels of protein in wildtype (WT) 
HEK293 cells with a band at ~110 kDa. The band is absent in NCSTN 
knockout (KO) cells. Both replicates show an unidentified band at 
25 kDa. B. The actin antibody shows the expected ~42 kDa band in 
both replicates of wildtype and knockout cells. Abbreviations: rep., 
replicate.
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protein. It is unclear how well the antibody would work for 
cell staining due to the non-specific 25 kDa band we observed 
on nicastrin blots. Based on these data obtained with the 
protocols described above, we can confirm the utility of this 
nicastrin antibody for immunoblotting.
Data availability
Source data
Home sapiens HEK293 NCSTN knockout by Cas9, Accession 
number: PRJNA268374
Figshare: HEK293 nicastrin knockout RT-qPCR. https://doi.
org/10.6084/m9.figshare.7578539.v118
This project contains the following source data:
•    knockout_rtqpcr.csv (Raw Ct values of RT-qPCR 
confirming the knockout (CRISPR-Cas9 mediated) of 
nicastrin in HEK293 cells.)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Underlying data
Figshare: NCSTN antibody validation - actin antibody in HEK293 
knockout line. https://doi.org/10.6084/m9.figshare.8952968.v119 
This project contains the following underlying data:
•    AntibodyValidation_NCSTN_KO_actin_Ab.svg (TIF 
image of actin antibody blot stored in a scaleable vector 
graphic file)
Figshare: NCSTN antibody validation - NCSTN antibody in 
HEK293 knockout line. https://doi.org/10.6084/m9.figshare. 
8952953.v120 
This project contains the following underlying data:
•    AntibodyValidation_NCSTN_KO_NCSTN_Ab.svg (TIF 
image of NCSTN antibody blot stored in a scaleable 
vector graphic file)
Figshare: NCSTN antibody validation - actin antibody in HEK293 
knockout line after PNGase treatment. https://doi.org/10.6084/
m9.figshare.8952983.v122 
This project contains the following underlying data:
•    AntibodyValidation_NCSTN_PNGase_actin_Ab.svg (TIF 
image of actin antibody blot stored in a scaleable vector 
graphic file)
Figshare: NCSTN antibody validation - NCSTN antibody in 
HEK293 knockout line after PNGase treatment. https://doi.
org/10.6084/m9.figshare.8952977.v123 
Figure 3. Nicastrin immunoblot with PNGase F treatment. A. In 
lysates untreated with PNGase F (-), the expected ~110 kDa band 
is present. With PNGase F treatment (+), the band regresses to less 
than 75 kDa. B. In both PNGase treated and untreated lysates, the 
beta actin band is unchanged.
Figure 4. Immunoblot of murine nicastrin. Blot showing the results 
for 35 µg (1) or 25 µg (2) of mouse membrane protein lysate. The 
expected ~110 kDa band for mature nicastrin is present, as is the 
non-specific band present in most blots at < 25 kDa. These data 
suggest the antibody works as well for murine nicastrin as it does 
for human nicastrin.
Conclusion
We tested by immunoblot an anti-nicastrin antibody using 
HEK293 cell lysates and mouse liver extracts. Our results show 
that the antibody is sensitive enough to detect endogenous 
protein with reasonable specificity. It is able to bind to both 
glycosylated nicastrin and nicastrin without sugar linkages. 
The antibody functions for both endogenous human and mouse 
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This project contains the following underlying data:
•    AntibodyValidation_NCSTN_PNGase_NCSTN_Ab.svg 
(TIF image of NCSTN antibody blot stored in a scaleable 
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This project contains the following underlying data:
•    SuppFig5_MouseNCSTN.svg (TIF image of NCSTN 
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